Compass Pathways' Psilocybin Therapy Shows Durable Efficacy in Phase 3 Trial — Compass Pathfinder Limited

Event summary

Compass Pathways reported six-month data from its second Phase 3 trial (COMP006) showing 39% of patients achieved clinically meaningful reduction in depression symptoms with COMP360 psilocybin therapy.
The trial involved nearly 600 patients with treatment-resistant depression, demonstrating durable effects through Week 26.
A rolling New Drug Application submission to the FDA is underway, with final submission expected in Q4 2026 and potential launch in H1 2027.
COMP360 showed a generally well-tolerated safety profile with most adverse events being transient.

The big picture

Compass Pathways' positive Phase 3 trial results for COMP360 psilocybin therapy mark a significant step toward potentially transforming treatment options for patients with treatment-resistant depression. The durable efficacy and safety profile demonstrated in large-scale trials could position COMP360 as a breakthrough therapy, pending regulatory approval. This development aligns with broader industry trends towards innovative mental health treatments that move beyond traditional antidepressants.

What we're watching

Regulatory Approval: Whether the FDA will approve COMP360 psilocybin therapy for treatment-resistant depression by H1 2027, following the completion of the rolling NDA submission.
Market Adoption: The pace at which COMP360 could be integrated into standard mental health care practices if approved, given its potential to offer a novel treatment option for chronic depression.
Competitive Landscape: How Compass Pathways will position itself against emerging competitors in the psychedelic therapy space as the market evolves.